Peripheral CD19⁺ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

RECOMMENDED

Multiple Sclerosis

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Lancet Neurol.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

doi: 10.1016/S1474-

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

RECOMMENDED

Further Publications NeurologyFurther Publications Psychiatry

Brain and cord imaging features in neuromyelitis optica spectrum disorders

Ann Neurol.

Cacciaguerra L, Meani A, Mesaros S, Radaelli M, Palace J, Dujmovic-Basuroski I, Pagani E, Martinelli V, Matthews L, Drulovic J, Leite MI, Comi G, Filippi M, Rocca MA

doi: 10.1002/ana.25411.

Multiple Sclerosis

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

Cell.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R

doi: 10.1016/j.cell.2018.08.011.

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

JAMA Neurol.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

doi: 10.1001/

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

J Neurol Neurosurg Psychiatry.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group)

doi: 10.1136/jnnp-2017-315603.

RECOMMENDED

Multiple Sclerosis

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

★ 3 Recommended by Prof. Dr Christian Kamm, Faculty Member

N Engl J Med.

Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J

doi: 10.1056/NEJMoa1901747.

RECOMMENDED

Multiple Sclerosis

Advances in oral immunomodulating therapies in relapsing multiple sclerosis

★ 3 Recommended by Prof. Dr Christian Kamm, Faculty Member

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Lancet Neurol.

Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L

doi: 10.1016/S1474-4422(19)30391-6.

Related content

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Vaccination Readiness in Multiple Sclerosis

Brain and cord imaging features in neuromyelitis optica spectrum disorders

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Advances in oral immunomodulating therapies in relapsing multiple sclerosis